Recombinant rabbit monoclonal antibodies have historically remained elusive due to intellectual property and technological barriers. Rabbit antibodies have unique advantages that make them ideal for research or diagnostic uses or as sources of therapeutic lead candidates. Due to higher diversity within antigen binding regions (CDRs), rabbit antibodies created from immunized sources have higher affinity compared to their mouse counterparts. Rabbit antibodies typically possess picomolar KD binding affinities, making affinity maturation unnecessary.
Rabbit monoclonal antibodies are typically derived from hybridomas, which are commonly poorly characterized and can exhibit high batch-to-batch variability. Hybridoma library screening is also limited (104-105), often missing rare clones that recognize important, less immunodominant epitopes. Abwiz Bio has solved these issues through a proprietary recombinant rabbit monoclonal antibody development platform, RabWizTM.
Abwiz Bio is pleased to perform contract work and to engage in co-development partnerships with a variety of research institutions and pharmaceutical companies. Abwiz Bio offers a variety of services that leverage our world-class, proprietary technology platform. Our partnership structure is highly flexible, and we are excited and interested in pursuing partnerships with pharmaceutical companies, research institutes or individual academic researchers. Call or e-mail us today to see how we can help you achieve your goals.
Phage display based antibody generation
RabWiz™ employs Abwiz Bio’s proprietary Needle-in-a-Haystack™ phage display technology and patented antibody library cloning method WizAmp™. This combines conventional animal immunization protocols with the robustness of phage display. These together enable the generation of antibodies with affinities typically attained only through hybridoma development, but doing so with the speed and diversity of phage display technology. The process allows for efficient, high throughput identification of rare binders with distinctive characteristics required for a specific application. Using this system, Abwiz Bio can create antibodies that recognize targets that have traditionally been difficult to attain, such as GPCRs and ion channels.
High affinity rabbit antibodies can be created in less than 6 months from the date of rabbit immunization. Abwiz Bio’s monoclonal antibody development platform is coupled with our friendly business terms (no royalties and minimal upfront fee).
Project development timeline
Step I - Rabbit Immunization
Step II - Library Construction
Step III - Phage Selection
Step IV - Recombinant Antibody Small-Scale Production
Step V - Recombinant Antibody Large-Scale Production